Balyasny Asset Management LLC Moon Lake Immunotherapeutics Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Balyasny Asset Management LLC holds 360,200 shares of MLTX stock, worth $18.4 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
360,200
Previous 584,263
38.35%
Holding current value
$18.4 Million
Previous $25.7 Million
29.31%
% of portfolio
0.03%
Previous 0.05%
Shares
9 transactions
Others Institutions Holding MLTX
# of Institutions
124Shares Held
58.2MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$1.11 Billion34.86% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$435 Million30.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.98MShares$152 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$142 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$119 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.89B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...